Abstract
Background: Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer. Methods: Using the Yonsei Tumor Registry database, patients with T1-3, N0-3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival. Results: The median age of the study population was 45 years (range, 23-76 years) and the median follow-up duration was 10.8 years (range, 0.1-25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 %, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 %, P < 0.001), and event free-free survival (EFS) (by 9.25 %, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL's parameters. The observed 10-year OS (61.4 %), BCSS (62.3 %), and EFS (59.1 %) and the KAOL predicted OS (61.5 %), BCSS (63.5 %) and EFS (57.6 %) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively). Conclusions: AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients.
| Original language | English |
|---|---|
| Pages (from-to) | 2615-2624 |
| Number of pages | 10 |
| Journal | Annals of Surgical Oncology |
| Volume | 20 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2013 Aug 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Oncology
Cite this
}
Application of the adjuvant! Online model to korean breast cancer patients : An assessment of prognostic accuracy and development of an alternative prognostic tool. / Jung, Minkyu; Choi, Eun Hee; Nam, Chung Mo; Rha, SunYoung; Jeung, Hei Cheul; Lee, Soo Hyun; Yang, Woo Ick; Roh, Jae Kyung; Chung, Hyuncheol.
In: Annals of Surgical Oncology, Vol. 20, No. 8, 01.08.2013, p. 2615-2624.Research output: Contribution to journal › Article
TY - JOUR
T1 - Application of the adjuvant! Online model to korean breast cancer patients
T2 - An assessment of prognostic accuracy and development of an alternative prognostic tool
AU - Jung, Minkyu
AU - Choi, Eun Hee
AU - Nam, Chung Mo
AU - Rha, SunYoung
AU - Jeung, Hei Cheul
AU - Lee, Soo Hyun
AU - Yang, Woo Ick
AU - Roh, Jae Kyung
AU - Chung, Hyuncheol
PY - 2013/8/1
Y1 - 2013/8/1
N2 - Background: Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer. Methods: Using the Yonsei Tumor Registry database, patients with T1-3, N0-3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival. Results: The median age of the study population was 45 years (range, 23-76 years) and the median follow-up duration was 10.8 years (range, 0.1-25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 %, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 %, P < 0.001), and event free-free survival (EFS) (by 9.25 %, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL's parameters. The observed 10-year OS (61.4 %), BCSS (62.3 %), and EFS (59.1 %) and the KAOL predicted OS (61.5 %), BCSS (63.5 %) and EFS (57.6 %) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively). Conclusions: AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients.
AB - Background: Adjuvant! Online (AOL) is a Web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy for breast cancer. Methods: Using the Yonsei Tumor Registry database, patients with T1-3, N0-3, M0 breast cancer who were treated at the Yonsei Cancer Center between 1986 and 1999 were entered into AOL version 8.0 to calculate survival. Results: The median age of the study population was 45 years (range, 23-76 years) and the median follow-up duration was 10.8 years (range, 0.1-25.9 years) for all 699 patients. AOL significantly overestimated overall survival (OS) (by 11.1 %, P < 0.001), breast cancer-specific survival (BCSS) (by 11.6 %, P < 0.001), and event free-free survival (EFS) (by 9.25 %, P < 0.001) in Korean patients. Therefore, we developed a Korean version of AOL (KAOL), which is a new model for prognosis based on AOL's parameters. The observed 10-year OS (61.4 %), BCSS (62.3 %), and EFS (59.1 %) and the KAOL predicted OS (61.5 %), BCSS (63.5 %) and EFS (57.6 %) were not different (P = 0.976, P = 0.771, and P = 0.674, respectively). Conclusions: AOL was not found to be suitable in Korean patients with breast cancer. The newly developed KAOL accurately predicted 10-year outcomes in Korean breast cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84880293360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880293360&partnerID=8YFLogxK
U2 - 10.1245/s10434-013-2956-z
DO - 10.1245/s10434-013-2956-z
M3 - Article
VL - 20
SP - 2615
EP - 2624
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 8
ER -